Recurrent Kaposi Sarcoma
8
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (8)
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma